The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated ... about the short-term safety of these drugs,” the authors write. “Nevertheless, evidence was ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...

Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as GLP-1 receptor agonists soared nearly 600% between 2020 and 2023 in people ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

At the same time, commodity prices continue to fluctuate as does demand – especially as more Americans are prescribed GLP-1 agonist drugs for weight loss and dramatically shift and reduce their ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.